Titan Pharmaceuticals INC 8-K filings

Titan Pharmaceuticals, Inc. completed its business combination with Black Titan Corporation, resulting in TTNP becoming a wholly-owned subsidiary and its shares converting to Black Titan Ordinary Shares.

Titan Pharmaceuticals, Inc. stockholders approved the proposed business combination with Black Titan Corporation and TalenTec Sdn. Bhd. at a special meeting.

Titan Pharmaceuticals, Inc. has completed a private placement, raising $600,000 through the issuance of Series C Convertible Preferred Stock to Blue Harbour Asset Management L.L.C-FZ.

Titan Pharmaceuticals, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the election of five directors, the issuance of over 20% of common stock for a private placement, and an amendment to its equity incentive plan.

Titan Pharmaceuticals, Inc. announced the filing of a Form F-4 registration statement with the SEC, including a preliminary proxy statement/prospectus, for its proposed reverse merger with TalenTec Sdn. Bhd. under the new holding company, Black Titan Corporation.

Titan Pharmaceuticals, Inc. has completed the conversion of Series AA and Series B Convertible Preferred Stock held by The Sire Group Ltd. and Blue Harbour Asset Management L.L.C-FZ into common stock, resulting in the issuance of 415,000 new common shares.

Titan Pharmaceuticals completed a $1 million private placement of convertible preferred stock to address Nasdaq's minimum stockholders' equity requirement.

Titan Pharmaceuticals enters into a securities purchase agreement with Blue Harbour Asset Management, issuing Series B Convertible Preferred Stock for $1 million to bolster its financial position.

Titan Pharmaceuticals has received a notice from Nasdaq for failing to hold its annual shareholder meeting within the required timeframe, potentially leading to delisting.

Titan Pharmaceuticals has appointed a new CEO, Chay Weei Jye, and a new independent auditor, Enrome LLP, effective December 2, 2024.

Titan Pharmaceuticals is at risk of delisting from the Nasdaq due to a late quarterly filing and is also non-compliant with audit committee requirements.

Titan Pharmaceuticals has appointed board member Brynner Chiam as acting principal executive officer and acting principal financial officer while the company searches for a permanent CEO.

Titan Pharmaceuticals' CEO and Chairman, Dato Seow Gim Shen, has resigned for personal reasons, prompting a search for a new leader.

Titan Pharmaceuticals has entered into a merger agreement with KE Sdn. Bhd., a human capital management solutions provider, in a reverse merger transaction.

Titan Pharmaceuticals has announced the resignation of several key executives and directors, along with the appointment of new board members, effective April 2, 2024.

Titan Pharmaceuticals has determined that its financial statements for the quarter ended September 30, 2023, should no longer be relied upon due to a misclassification of $406,000 in expenses.

Titan Pharmaceuticals issued 54,132 shares of common stock to Choong Choon Hau after he converted a $500,000 convertible note.

Titan Pharmaceuticals has extended the term of its Senior Vice President of Finance and principal accounting officer, Brian Crowley, through May 15, 2024, while the board continues its search for a permanent replacement.

Titan Pharmaceuticals has been notified by Nasdaq that it has regained compliance with the minimum $1.00 bid price requirement, allowing it to continue listing on the Nasdaq Capital Market.

Titan Pharmaceuticals' Senior Vice President of Finance and Administration, Brian Crowley, has resigned, effective February 2, 2024.